Department of Neurosurgery, The Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University, 261 Huansha Road, Hangzhou 310006, China.
Department of Intensive Care Unit, The Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University, 261 Huansha Road, Hangzhou 310006, China.
Clin Chim Acta. 2018 Nov;486:335-340. doi: 10.1016/j.cca.2018.08.036. Epub 2018 Aug 23.
Cleaved receptor for advanced glycation end-products (cRAGE) has been introduced as a new inflammatory marker. We clarified the associations between cRAGE levels, disease severity and functional outcome in aneurysmal subarachnoid hemorrhage (aSAH).
In this prospective, observational study, plasma levels of total soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) were quantified in 108 aSAH patients and 108 controls. The level of cRAGE was calculated by subtracting the level of esRAGE from that of sRAGE. World Federation of Neurological Surgeons (WFNS) score, modified Fisher score, and Hunt Hess (HH) score were recorded to assess aSAH severity. Relationship between plasma cRAGE levels and 6-month poor outcome (Glasgow Outcome Scale score of 1-3) was assess using multivariate analysis.
Plasma cRAGE levels were significantly higher in patients than in controls. Its levels were significantly correlated with WNFS score, modified Fisher score and HH score of patients. Plasma cRAGE emerged as an independent predictor for 6-month poor outcome. Area under receiver operating characteristic curve (AUC) of this biomarker was similar to those of WNFS score, modified Fisher score and HH score. Moreover, it significantly improved AUCs of WNFS score, modified Fisher score and HH score.
Plasma cRAGE levels are highly associated with the severity and poor prognosis in aSAH.
晚期糖基化终产物受体（cRAGE）作为一种新的炎症标志物被提出。我们阐明了 cRAGE 水平与动脉瘤性蛛网膜下腔出血（aSAH）的严重程度和功能预后之间的关系。
在这项前瞻性、观察性研究中，我们定量检测了 108 例 aSAH 患者和 108 例对照者的血浆总可溶性 RAGE（sRAGE）和内源性分泌型 RAGE（esRAGE）水平。通过从 sRAGE 水平中减去 esRAGE 水平来计算 cRAGE 水平。记录世界神经外科联合会（WFNS）评分、改良 Fisher 评分和 Hunt-Hess（HH）评分，以评估 aSAH 的严重程度。使用多变量分析评估血浆 cRAGE 水平与 6 个月不良预后（格拉斯哥预后量表评分 1-3）之间的关系。
患者的血浆 cRAGE 水平明显高于对照组。其水平与患者的 WFNS 评分、改良 Fisher 评分和 HH 评分显著相关。血浆 cRAGE 是 6 个月不良预后的独立预测因子。该生物标志物的受试者工作特征曲线（ROC）下面积（AUC）与 WFNS 评分、改良 Fisher 评分和 HH 评分相似。此外，它显著提高了 WFNS 评分、改良 Fisher 评分和 HH 评分的 AUC。
血浆 cRAGE 水平与 aSAH 的严重程度和不良预后密切相关。
